Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
SKRR to Commence Uranium Drill Program to Test Conductors at Clearwater West (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Atossa Therapeutics Inc ATOS

Healthcare Biotechnology
Atossa Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It is engaged in developing medicines in areas of significant unmet medical need in oncology with a focus on using (Z)-endoxifen to prevent and treat breast cancer. Its lead drug candidate under development is oral (Z)-endoxifen, which it is developing for both the prevention and treatment of breast cancer. (Z)-endoxifen... see more

Recent & Breaking News (NDAQ:ATOS)

Atossa Genetics to Present at the 4th Annual Precision: Breast Cancer World R&D Summit April 25, 2019

GlobeNewswire April 22, 2019

Atossa Genetics Announces Year End 2018 Financial Results and Provides Company Update

GlobeNewswire March 28, 2019

71 Biggest Movers From Yesterday

Benzinga.com  March 28, 2019

31 Stocks Moving In Wednesday's Pre-Market Session

Benzinga.com  March 27, 2019

58 Biggest Movers From Yesterday

Benzinga.com  March 27, 2019

Atossa Genetics Announces Institutional Review Board Approval of Oral Endoxifen as Post-Mastectomy Treatment for a U.S. Breast Cancer Patient

GlobeNewswire March 26, 2019

41 Stocks Moving In Wednesday's Mid-Day Session

Benzinga.com  March 20, 2019

Atossa Genetics Announces Receipt of $10 Million

GlobeNewswire March 18, 2019

Thinking about buying stock in Atossa Genetics Inc., Canopy Growth Corp., Facebook Inc., Micron Technology Inc., or Oxbridge Holdings?

PR Newswire March 15, 2019

32 Stocks Moving In Friday's Pre-Market Session

Benzinga.com  March 15, 2019

Mid-Afternoon Market Update: MongoDB Surges On Upbeat Q4 Results; Tailored Brands Shares Tumble

Benzinga.com  March 14, 2019

56 Stocks Moving In Thursday's Mid-Day Session

Benzinga.com  March 14, 2019

Mid-Day Market Update: Smith Micro Software Rises Following Strong Q4 Results; FTD Companies Shares Drop

Benzinga.com  March 14, 2019

Atossa Genetics Announces FDA Approval of Oral Endoxifen for “Expanded Access” as Post-Mastectomy Treatment for a U.S. Breast Cancer Patient

GlobeNewswire March 14, 2019

72 Biggest Movers From Yesterday

Benzinga.com  February 8, 2019

54 Stocks Moving In Thursday's Mid-Day Session

Benzinga.com  February 7, 2019

Mid-Morning Market Update: Markets Open Lower; Twitter Shares Drop After Light Forecast

Benzinga.com  February 7, 2019

Atossa Genetics Reports Results From “Expanded Access” Program for a U.S. Breast Cancer Patient Taking Oral Endoxifen: Sizeable Reduction in Cancer Cell Biological Activity; No Safety or Tolerability Issues

GlobeNewswire February 7, 2019

Atossa Genetics Provides Breast Cancer Prevention Recommendations to the United States Preventative Services Task Force

GlobeNewswire February 4, 2019

Atossa Genetics President and CEO Dr. Steven C. Quay Issues Annual Letter to Shareholders Highlighting Key Accomplishments and Strategy for 2019

GlobeNewswire January 28, 2019